Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients.
Phase of Trial: Phase IV
Latest Information Update: 07 May 2017
At a glance
- Drugs Ezetimibe/simvastatin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms BRAVO
- Sponsors Merck & Co
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2010 Actual initiation date changed from Jan 2007 to Aug 2007 as reported by ClinicalTrials.gov.
- 25 Aug 2010 Actual end date changed from Feb 2009 to Jul 2009 as reported by ClinicalTrials.gov.